19 Patent No. 6754749, JP Patent No. 7217245, KR Patent No. 10-2416359, KR Patent No. 10-2562175, and MX Patent No. 365521 US 8,765,432, US 11,819,531, US Appl. No. 18/490,182, AU Patent No. 2010330727, BR Patent No. 1120120145568, CA Patent No. 2783615, CA Patent No. 3039426, EP Patent No. 2512462, EP Patent No. 3254678, EP Patent No. 3659591, CN Patent No. ZL201080062252.7, HK Patent No. 1247828, IN Patent No. 319269, JP Patent No. 5760007, JP Patent No. 5990629, JP Patent No. 6416832, JP Patent No. 6777706, MX Patent No. 346423, MX Patent No. 374020, KR Patent No. 10- 1852044, and MO Patent No. J/002943 5/10/2030 Representative claims include copolymers and methods of making copolymers (ABC Platform specifically) US 10,702,608, US 11,590,235, US 12,214,044, EP Patent No. 3041513, JP Patent No. 6463361, JP Patent No. 6732056, JP Patent No. 7232796, and foreign applications in certain jurisdictions claiming priority to PCT/US2014/054622 12/21/2034 Representative claims include polymers and method of making polymers US 11,066,465, US Appl. No. 17/301599, AU Patent No. 2016381964, IL Patent No. 260323, JP Patent No. 7088454, JP Patent No. 7414371, MX Patent No. 407292, RU Patent No. 2744860, and foreign applications in certain jurisdictions claiming priority to PCT/US2016/069336 12/29/2036 Representative claims include antibody and antibody conjugate, and methods of making and using the conjugates US Patent No. 11,912,784, US Appl. No. 18/504723, and foreign applications in certain jurisdictions claiming priority to PCT/US2020/055074 10/9/2040 Representative claims include method of treating an eye disorder using the antibody conjugates US Appl. No. 18/555122, EP and HK applications claiming priority to PCT/US2022/024598 4/13/2042 Representative claims include method of treating an eye disorder using the antibody conjugates US Appl. No. 18/166755 and foreign applications in certain jurisdictions claiming priority to PCT/US2023/062322 2/9/2043 Representative claims include method of purifying the antibody conjugates PCT Application No. PCT/US2023/074805 9/21/2043 Representative claims include methods of preparing a protein solution or therapeutic formulation US Patent No. 12,071,476, US Appl. No. 18/736105 and foreign applications in certain jurisdictions claiming priority to PCT/US2019/020418 3/1/2039 Representative claims include fusion proteins and conjugates thereof, and methods of making and using the fusion proteins and the conjugates US Appl. No. 17/997866 and EP application claiming priority to PCT/US2021/031194 5/6/2041 Representative claims include method of treating a disorder related to an infection or a systemic inflammatory condition using fusion proteins and conjugates thereof